Dr Victor Musiime at IAS 2023. Photo by Roger Pebody/AidsmapA study which evaluated the outcomes of children switching from a first-line NNRTI-based treatment to a second-line treatment shows viable options that would increase access to safe and effective second-line antiretroviral therapy (ART). The findings highlight the need to develop a child-friendly fixed-dose combination of tenofovir alafenamide fumarate (TAF) and emtricitabine plus dolutegravir as an anchor medicine. Alternatively, darunavir or atazanavir could be used as the anchor.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.